Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 69

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 69
---
13/2024 | ​ | ​ | ​ | ​                                                                    | ​ |       ​ | ​ | ​ | ​ | ​                                                                | ​ | ​          | ​ | ​ | ​ | ​                                                             | ​ | 150,000(3) | ​ | ​ | ​ | ​                                     | ​ | 56.18 | ​ | ​ | ​ | ​                                         | ​ | 6,125,385 | ​ | ​ |
| ​                      | ​ | ​ | Annual Cash  | ​ | ​ | ​         | ​ | ​         | ​ | ​ | ​ | ​            | ​ | ​         | ​ | ​ | ​ | ​                                                                    | ​ | 270,000 | ​ | ​ | ​ | ​                                                                | ​ | ​          | ​ | ​ | ​ | ​                                                             | ​ | ​          | ​ | ​ | ​ | ​                                     | ​ |     ​ | ​ | ​ | ​ | ​                                         | ​ |         ​ | ​ | ​ |

(1) This column sets forth the target amount for each NEO for the year ended December 31, 2024 under our annual performance bonus program. There are no threshold or maximum values applicable. For a description of the Company’s annual performance bonus program for 2024, see “Compensation Discussion and Analysis — Elements of Our 2024 Executive Compensation Program — Annual Cash Performance Bonus” in this Proxy Statement. (2) Amounts reported represent the aggregate grant date fair value of time-vesting and performance-vesting option awards granted during 2024 under our 2020 Plan, computed in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in the notes to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the NEOs upon vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The grant date fair value of Dr. Seehra’s performance-vesting option awards is based on the probable outcome of the performance conditions as of the grant date. (3) Annual time-vesting options awarded under the 2020 Plan. Each option award vests as follows: 25% of the shares subject to the option vest on February 13,